Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
AIDS Behav. 2013 Jan;17(1):94-103. doi: 10.1007/s10461-012-0288-9.
Adherence to hepatitis C virus (HCV) therapy has been incompletely examined among HIV-infected patients. We assessed changes in interferon and ribavirin adherence and evaluated the relationship between adherence and early (EVR) and sustained virologic response (SVR). We performed a cohort study among 333 HIV/HCV-coinfected patients who received pegylated interferon and ribavirin between 2001 and 2006 and had HCV RNA before and after treatment. Adherence was calculated over 12-week intervals using pharmacy refills. Mean interferon and ribavirin adherence declined 2.5 and 4.1 percentage points per 12-week interval, respectively. Among genotype 1/4 patients, EVR increased with higher ribavirin adherence, but this association was less strong for interferon. SVR among these patients was higher with increasing interferon and ribavirin adherence over the first, second, and third, but not fourth, 12-week intervals. Among HIV/HCV patients, EVR and SVR increased with higher interferon and ribavirin adherence. Adherence to both antivirals declined over time, but more so for ribavirin.
在感染 HIV 的患者中，丙型肝炎病毒 (HCV) 治疗的依从性尚未得到充分研究。我们评估了干扰素和利巴韦林依从性的变化，并评估了依从性与早期（EVR）和持续病毒学应答（SVR）之间的关系。我们对 333 名 HIV/HCV 合并感染患者进行了队列研究，这些患者在 2001 年至 2006 年间接受了聚乙二醇干扰素和利巴韦林治疗，并在治疗前后检测了 HCV RNA。通过药房补药计算了 12 周的依从性。干扰素和利巴韦林的平均依从性每 12 周分别下降了 2.5 和 4.1 个百分点。在基因型 1/4 患者中，随着利巴韦林依从性的提高，EVR 增加，但干扰素的相关性较弱。对于这些患者，随着前 12 周、第 2 个 12 周和第 3 个 12 周的干扰素和利巴韦林依从性的增加，SVR 更高，但在第 4 个 12 周则没有。在 HIV/HCV 患者中，EVR 和 SVR 随着干扰素和利巴韦林依从性的提高而增加。两种抗病毒药物的依从性随时间下降，但利巴韦林下降得更明显。
